🔥🐔 BizChicken 🐔🔥
Companies Similar to Edgewise Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Enliven Therapeutics, Inc.
small molecule kinase inhibitors
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer treatment, including key products ELVN-001 and ELVN-002 under clinical trials.
About | About | Directors | About | Contact | Contact | Careers | Careers | Careers | Jobs | Careers | About | Vision/Values
Symbol: ELVN
Recent Price: $22.39
Industry: Biotechnology
CEO: Mr. Samuel S. Kintz M.B.A.
Sector: Healthcare
Employees: 52
Address: 6200 Lookout Road, Boulder, CO 80301
Phone: 720 647 8519
Leadership
- Sam Kintz, Co-founder, Chief Executive Officer, and Member of the Board of Directors
- Joe Lyssikatos, Co-founder, Chief Scientific Officer
- Anish Patel, Co-founder and Chief Operating Officer
- Helen Collins, Chief Medical Officer
- Ben Hohl, Chief Financial Officer and Head of Corporate Development
- Galya Blachman, Chief Legal Officer and Head of Business Development
- Rich A. Heyman, Chairman of the Board of Directors
- Rishi Gupta, Member of the Board of Directors
- Andy Phillips, Member of the Board of Directors
- Mika Kakefuda Derynck, Member of the Board of Directors
- Jake Bauer, Member of the Board of Directors
- Rahul Ballal, Member of the Board of Directors
- Lori Kunkel, Member of the Board of Directors
- Brian Druker, Scientific Advisor
- Kevin Koch, Scientific Advisor
Last updated: 2024-12-31
Gain Therapeutics, Inc.
Site-Directed Enzyme Enhancement Therapy platform
Gain Therapeutics, Inc. is a biotechnology company developing therapies for diseases caused by protein misfolding, focusing on rare genetic diseases and neurological disorders. It utilizes its proprietary technology to discover and develop molecules targeting misfolded proteins.
Symbol: GANX
Recent Price: $2.18
Industry: Biotechnology
CEO: Mr. Gene Mack M.B.A.
Sector: Healthcare
Employees: 29
Address: 4800 Montgomery Lane, Bethesda, MD 20814
Phone: 301 500 1556
Last updated: 2024-12-31
Dyne Therapeutics, Inc.
FORCE platform
Dyne Therapeutics, Inc. is a biotechnology company focused on advancing therapeutics for genetically driven muscle diseases, including myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, using its FORCE platform.
Symbol: DYN
Recent Price: $23.65
Industry: Biotechnology
CEO: Mr. John G. Cox M.B.A.
Sector: Healthcare
Employees: 152
Address: 1560 Trapelo Road, Waltham, MA 02451
Phone: 781 786 8230
Last updated: 2024-12-31
Eledon Pharmaceuticals, Inc.
AT-1501
Eledon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing medicines for autoimmune diseases, amyotrophic lateral sclerosis (ALS), and organ or cell-based transplants. Its lead product candidate AT-1501 is in Phase 2 clinical trials.
Symbol: ELDN
Recent Price: $4.14
Industry: Biotechnology
CEO: Dr. David-Alexandre C. Gros M.D., Ph.D.
Sector: Healthcare
Employees: 20
Address: 19900 MacArthur Boulevard, Irvine, CA 92612
Phone: 949 238 8090
Last updated: 2024-12-31
Elicio Therapeutics, Inc.
ELI-002
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.
Symbol: ELTX
Recent Price: $5.00
Industry: Biotechnology
CEO: Mr. Robert T. Connelly
Sector: Healthcare
Employees: 32
Address: 451 D Street, Boston, MA 02210
Phone: 857-209-0050
Last updated: 2024-12-31
Evelo Biosciences, Inc.
EDP1815
Evelo Biosciences, Inc. discovers and develops oral biologics for inflammatory diseases and cancer, with key products like EDP1815 in clinical trials.
Symbol: EVLO
Recent Price: $0.00
Industry: Biotechnology
CEO: Mr. Craig R. Jalbert CIRA
Sector: Healthcare
Employees: 66
Address: 620 Memorial Drive, Cambridge, MA 02139
Phone: 617 577 0300
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Apogee Therapeutics, Inc.
APG777, APG808, APG990, APG222
Apogee Therapeutics, Inc. is a biotechnology company developing biologics for the treatment of atopic dermatitis, COPD, and related inflammatory and immunology conditions. Founded in 2022 and based in Waltham, Massachusetts.
Symbol: APGE
Recent Price: $44.64
Industry: Biotechnology
CEO: Dr. Michael Thomas Henderson M.D.
Sector: Healthcare
Employees: 91
Address: 221 Crescent Street, Waltham, MA 02453
Phone: 650-394-5230
Last updated: 2024-12-31
Beam Therapeutics Inc.
precision genetic medicines
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.
About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About | About | Careers | About | Jobs | Careers
Symbol: BEAM
Recent Price: $25.28
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Sector: Healthcare
Employees: 472
Address: 238 Main Street, Cambridge, MA 02142
Phone: 857 327 8775
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Edgewise Therapeutics, Inc.
EDG-5506
Edgewise Therapeutics, Inc. is a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, including treatments for Duchenne muscular dystrophy and Becker muscular dystrophy.
About | Leadership | Contact | Contact | Careers | About | About | About | About | About | About
Symbol: EWTX
Recent Price: $27.05
Industry: Biotechnology
CEO: Dr. Kevin Koch Ph.D.
Sector: Healthcare
Employees: 97
Address: 3415 Colorado Avenue, Boulder, CO 80303
Phone: 303 735 8373
Leadership
- Kevin Koch, Ph.D., Director
- Alan Russell, Ph.D., Director and Co-Founder
- R. Michael Carruthers, Chief Financial Officer
- Behrad Derakhshan, Ph.D., Chief Business Officer
- Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer
- John Moore, General Counsel
- Marc Semigran, M.D., Chief Development Officer
- Peter Thompson, M.D., Chairman and Co-Founder
- Laura Brege, Director
- Badreddin Edris, Ph.D., Director and Co-Founder
- Jonathan C. Fox, M.D., Ph.D., FACC, Director
- Arlene Morris, Director
- Jon Root, M.D., Director
Last updated: 2024-12-31
EyeGate Pharmaceuticals, Inc.
EGP-437
Eye Gate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.
About | Vision/Values | Directors | About | Management | Contact
Symbol: EYEG
Recent Price: $35.04
Industry: Biotechnology
CEO: Mr. Stephen From
Sector: Healthcare
Employees: 14
Address: 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS 02452
Phone: 17817889043
Leadership
- Paul Chaney, Chairman of the Board
- Morton F. Goldberg, MD, Director
- Praveen Tyle, PhD, Director
- Thomas Balland, Director
- Thomas E. Hancock, Director
- Bernard Malfroy-Camine, PhD, Director
- Mounia Chaoui, PhD, Director
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
PepGen Inc.
PGN-EDO51
Pep Gen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for neuromuscular and neurologic diseases. Its lead product, PGN-EDO51, is in Phase I trials for Duchenne muscular dystrophy.
Symbol: PEPG
Recent Price: $3.83
Industry: Biotechnology
CEO: Dr. James G. McArthur Ph.D.
Sector: Healthcare
Employees: 72
Address: 245 Main Street, Cambridge, MA 02142
Phone: 781-797-0979
Last updated: 2024-12-31
PTC Therapeutics, Inc.
Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.
About | History | Leadership | About | Contact | Careers | Careers | Jobs | About | About | About | About
Symbol: PTCT
Recent Price: $45.77
Industry: Biotechnology
CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Sector: Healthcare
Employees: 988
Address: 100 Corporate Court, South Plainfield, NJ 07080
Phone: 908 222 7000
Leadership
- Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
- Neil Almstead, Ph.D., Chief Technical Operations Officer
- John Baird, Ph.D., Chief of Staff to the CEO
- Mark E. Boulding, Executive Vice President and Chief Legal Officer
- Lee Golden, M.D., Chief Medical Officer
- Pierre Gravier, Chief Financial Officer
- Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
- Linda Montella-Carter, Senior Vice President and Chief Information Officer
- Eric Pauwels, Chief Business Officer
- Hege Sollie-Zetlmayer, Chief Human Resources Officer
- Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
- Michael Schmertzler, Chairman
- William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
- Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
- Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
- Emma Reeve, Independent Board Director
- Mary Smith, The VENG Group
- David P. Southwell, Former CEO, TScan Therapeutics
- Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
- Alethia Young, Chief Financial Officer, Bicycle Therapeutics
- Jerome B. Zeldis, M.D., Ph.D., Independent Board Director
Last updated: 2024-12-31
Entrada Therapeutics, Inc.
ENTR-601-44
Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for treating neuromuscular diseases, with a lead product candidate ENTR-601-44 in preclinical trials for Duchenne muscular dystrophy and myotonic dystrophy type 1.
About | Contact | Contact | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Careers | Careers | About
Symbol: TRDA
Recent Price: $17.37
Industry: Biotechnology
CEO: Mr. Dipal Doshi
Sector: Healthcare
Employees: 168
Address: 6 Tide Street, Boston, MA 02210
Phone: 857 520 9158
Last updated: 2024-12-31
Verve Therapeutics, Inc.
VERVE-101
Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.
Symbol: VERV
Recent Price: $5.54
Industry: Biotechnology
CEO: Dr. Sekar Kathiresan M.D.
Sector: Healthcare
Employees: 255
Address: 500 Technology Square, Cambridge, MA 02139
Phone: 617 603 0070
Leadership
- Andrew Ashe, President, Chief Operating Officer and General Counsel
- Victoria Bartlett, Vice President, Program and Alliance Management
- Dan Balian, Associate Director, Supply Chain Management
- Allen Barrett, Director, Corporate Counsel
Last updated: 2024-12-31
Aligos Therapeutics, Inc.
ALG-010133
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for viral and liver diseases, with a focus on chronic hepatitis B and non-alcoholic steatohepatitis.
Careers | About | Management | Management | Contact | About | About
Symbol: ALGS
Recent Price: $40.47
Industry: Biotechnology
CEO: Dr. Lawrence M. Blatt MBA, Ph.D.
Sector: Healthcare
Employees: 68
Address: One Corporate Drive, South San Francisco, CA 94080
Phone: 800 466 6059
Last updated: 2024-12-31
Stoke Therapeutics, Inc.
STK-001, STK-002
Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines to treat genetic diseases. Their lead product, STK-001, is aimed at treating Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.
Symbol: STOK
Recent Price: $10.80
Industry: Biotechnology
CEO: Dr. Edward M. Kaye M.D., Ph.D.
Sector: Healthcare
Employees: 110
Address: 45 Wiggins Avenue, Bedford, MA 01730
Phone: 781 430 8200
Leadership
- Edward M. Kaye, M.D., Chief Executive Officer & Director
- Jonathan Allan, J.D., General Counsel
- Isabel Aznarez, Ph.D., Senior Vice President, Discovery Research and Co-Founder
- Jason Hoitt, Chief Commercial Officer
- Dawn Kalmar, Chief Communications Officer
- Tommy Leggett, Chief Financial Officer
- Shamim Ruff, Chief Regulatory Officer
- Barry S. Ticho, M.D., Ph.D., FACC, Chief Medical Officer
- Joan Wood, Chief Human Resources Officer
- Adrian Krainer, Ph.D., Co-founder & Director
- Arthur Tzianabos, Ph.D., Chairman
- Jennifer Burstein, MBA, CPA, Director
- Seth L. Harrison, M.D., Director
- Arthur Levin, Ph.D., Director
- Garry E. Menzel, Ph.D., MBA, Director
- Ian F. Smith, Director
- Julie Anne Smith, Director
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31